Form 4: Ionis Pharmaceuticals EVP Sells Shares Under 10b5-1 Trading Plan

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 6,165 shares of common stock at an average price of $31.6203 on February 4, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 4, 2025, Patrick R. O'Neil, the EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 6,165 shares of the company's common stock.
• The shares were sold at a weighted average price of $31.6203.
• The sale was executed under a Rule 10b5-1 trading plan adopted on February 21, 2024.
• Following the transaction, O'Neil directly owns 57,452 shares of Ionis Pharmaceuticals.
• The prices for the shares sold ranged from $31.56 to $31.715.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an executive stock sale under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Sales under 10b5-1 plans are generally viewed as less impactful since they are pre-arranged and not based on current insider information. Investors often monitor insider transactions for signals about a company's prospects, but 10b5-1 sales are typically less informative.

Comparison to Industry Standards

• Executive compensation practices, including stock sales, are generally benchmarked against peer companies in the biotechnology and pharmaceutical industries.
• Companies like Alnylam Pharmaceuticals, Biogen, and Vertex Pharmaceuticals are often considered peers of Ionis Pharmaceuticals.
• The use of 10b5-1 trading plans is a standard practice among executives to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but given the relatively small number of shares sold and the use of a 10b5-1 plan, the impact is likely to be minimal.

Key Dates

Keywords

Ionis Pharmaceuticals, Patrick R. O'Neil, stock sale, Form 4, 10b5-1 trading plan, executive compensation, insider trading